Acknowledgments
LIVER, HANSEN, LARSEN, JENSEN
We thank Louise Skovborg Just, Lise Ryborg, and Helene Bæk Juel for Consortia project coordination; hepatology nurse specialists Trine Møller, Charlotte Damby Jensen, Minna Ingham, Line Jensen, Maria Fogt, Helle Lindholm Schnefeld, and Julie Hansen; the participant recruiting team including Jonas Dragsbæk Larsen and Freja Pelck Hansen; the GCP monitor Tanja Busk Bidstrup; Mette Andreasen, Anette Tyrsted, and Lea Grip from the Open Patient data Explorative Network; the entire staff at the Odense Municipal Alcohol Rehabilitation Centre; the Odense University Hospital Pharmacy; Jane Møller Jensen, Simon Langkjær Sørensen, and the entire staff at the Odense Liver Research Centre; Marianne Bergman from the Biochemical Department, Lillebaelt Hospital; the hepatology research team at Nordic Bioscience, Mette Juul Nielsen and Ida Villesen; Norgine Denmark for trial medication sponsored unconditionally and free of charge; and all partners of the Galaxy Consortium and The MicrobLiver Consortium. The EU Program for Science and Innovation (GALAXY; fund number 668031) and The Novo Nordisk Foundation (MicrobLiver; fund number NNF15OC0016692) funded the study. Norgine, Denmark, provided unconditionally and free of charge the active treatment and matching placebo for the study and did not influence the study design, data analyses, or interpretation.